-

JDRF and Tandem Diabetes Care Partner to Help Educate and Support the T1D Community

SAN DIEGO--(BUSINESS WIRE)--JDRF, the leading global organization funding type 1 diabetes (T1D) research, and Tandem Diabetes Care (NASDAQ: TNDM), a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience, announce a new national partnership to help drive awareness and education on topics related to technology innovation, diabetes management, and healthcare for people with diabetes.

The partnership will utilize JDRF’s community facing platforms, including local chapter events, digital channels, and education programs, to bring to life the benefits of devices such as insulin pumps, continuous glucose monitors and novel treatment approaches like hybrid closed loop therapy.

“Together, we will show how innovations in type 1 diabetes management and care will continue to minimize the intrusions of T1D on day-to-day life and provide better health outcomes for people living with the disease,” said Joe Watterson, JDRF Vice President of Corporate Development.

People living with T1D have a variety of needs that span from reducing the daily burden of disease management to finding a trusted technology partner who can deliver solutions that work reliably, provide clinical benefits, and improve their overall quality of life. The JDRF and Tandem partnership aims to actively support the growing needs of the T1D community and help address the gap in diabetes education on these topics through regional and local activities, including select Type One Nation Summits and JDRF One Walk events.

“Education is the foundation for improved quality of life and clinical outcomes for people with type 1 diabetes, and we are proud to partner with JDRF in furthering our shared mission to support the diabetes community,” said Brian Hansen, Executive Vice President and Chief Commercial Officer at Tandem Diabetes Care.

About JDRF

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Contacts

JDRF Contact Information:
Ayana Young, 347-496-2494, ayoung@jdrf.org

Tandem Diabetes Care Contact Information:
Media: Steve Sabicer, 714-907-6264, ssabicer@thesabicergroup.com
Investors: Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Summary
JDRF and Tandem Diabetes Care partner to help educate and support the T1D community.
Release Versions

Contacts

JDRF Contact Information:
Ayana Young, 347-496-2494, ayoung@jdrf.org

Tandem Diabetes Care Contact Information:
Media: Steve Sabicer, 714-907-6264, ssabicer@thesabicergroup.com
Investors: Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care, Inc.

Tandem Mobi Now Compatible with Android Smartphones

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world’s smallest, durable automated insulin delivery system,1 can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. "By expanding to Android, we’re broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes," said John Sheridan, president and chief...

Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a...

Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “S...
Back to Newsroom